Immunotherapy of canine leishmaniasis
Inventors
Chang, Kwang-Poo • MANNA, Laura • CORSO, Raffaele • KOLLI, Bala K.
Assignees
Rosalind Franklin University of Medicine and Science
Publication Number
US-11219677-B2
Publication Date
2022-01-11
Expiration Date
2038-05-03
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides a method for treating canine leishmaniasis by immunotherapy.
Core Innovation
The invention provides a method for treating canine leishmaniasis using a combination of chemotherapy and immunotherapy through photodynamic vaccination. The treatment includes administering an effective amount of a chemotherapeutic agent to canines diagnosed with leishmaniasis, alongside a solution containing photo-inactivated Leishmania at a concentration of 107/0.1 ml.
Photodynamic therapy employs photosensitizers that, when activated by light, generate cytotoxic reactive oxygen species to eliminate diseased cells or pathogens. Leishmania's ability to reside within antigen-presenting cells makes it a suitable carrier for vaccine delivery, allowing for cell-mediated immunotherapy to target difficult-to-cure diseases such as canine leishmaniasis.
The invention addresses the limitations of current treatments, which require prolonged use of toxic drugs and are associated with frequent disease relapses. By combining a specific chemotherapeutic regimen with immunotherapy using photo-inactivated Leishmania, the method aims to improve clinical prognosis and potentially overcome the problem of drug resistance.
Claims Coverage
There is one independent claim defining the main inventive features of this invention.
Method of treating canine leishmaniasis by sequential chemotherapy and photodynamic vaccination
A method comprising: 1. Administering a chemotherapeutic agent to a canine diagnosed with leishmaniasis, specifically an antimony-containing compound, meglumine antimoniate given subcutaneously at 100 mg/kg/day for 30 days, followed by subcutaneous allopurinol at a daily maintenance dose of 10 mg/kg/day. 2. Periodically administering immunotherapy to the canine after the chemotherapeutic agent administration is completed, with a vaccine solution containing photo-inactivated Leishmania at 107/0.1 ml.
The inventive features claimed encompass a combined therapeutic approach using specific chemotherapeutic administration followed by periodic immunotherapy with photo-inactivated Leishmania for treatment of canine leishmaniasis.
Stated Advantages
The immunotherapy, when used together with conventional chemotherapy and maintenance with allopurinol, was found to stop relapse of the disease completely and worked better than using allopurinol alone.
The immunotherapy appears to boost the feeble immunity expected to develop after chemotherapy.
Documented Applications
Treatment of canine leishmaniasis.
Prophylactic and therapeutic trials for canine leishmaniasis.
Interested in licensing this patent?